Listed

Compass Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2023

Filed with the SEC on Aug 3, 2023 and accepted by EDGAR at Aug 3, 2023, 12:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income3 months2023-04-01 to 2023-06-30−$13.3mus-gaap:OperatingIncomeLoss
Operating income6 months2023-01-01 to 2023-06-30−$23.0mus-gaap:OperatingIncomeLoss
Income tax3 months2023-04-01 to 2023-06-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax6 months2023-01-01 to 2023-06-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-04-01 to 2023-06-30−$11.3mus-gaap:NetIncomeLoss
Net income6 months2023-01-01 to 2023-06-30−$19.1mus-gaap:NetIncomeLoss
Basic EPS3 months2023-04-01 to 2023-06-30−$0.09us-gaap:EarningsPerShareBasic
Basic EPS6 months2023-01-01 to 2023-06-30−$0.15us-gaap:EarningsPerShareBasic
Operating cash flow6 months2023-01-01 to 2023-06-30−$22.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2023-01-01 to 2023-06-30$11.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-06-30$19.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-06-30$175.3mus-gaap:AssetsCurrent
Total assetsAt period end2023-06-30$179.2mus-gaap:Assets
Current liabilitiesAt period end2023-06-30$9.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-06-30$10.9mus-gaap:Liabilities
Shareholders' equityAt period end2023-06-30$168.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-23-004947. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.